Trial Profile
A Phase I/II, Multicenter, Open-label Study of Oral FGF401 in Adult Patients With Hepatocellular Carcinoma or Solid Malignancies Characterized by Positive FGFR4 and KLB Expression
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Roblitinib (Primary) ; Spartalizumab
- Indications Liver cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 30 Jul 2019 Status changed from active, no longer recruiting to completed.
- 30 Jul 2019 This trial has been discontinued in Germany, according to European Clinical Trials Database.
- 22 May 2019 This trial has been completed in Spain, according to European Clinical Trials Database.